Metropolitan Life Insurance CO Esperion Therapeutics, Inc. Transaction History

Metropolitan Life Insurance CO

$281 Million
Q3 2024

38 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jun 14, 2023	BUY	$5.09 - $8.5 $20,522 - $34,272	4,032 New	4,032 $25.1 Million
Q3 2022 Jun 14, 2023	BUY	$5.45 - $8.13 $21,974 - $32,780	4,032 New	4,032 $27 Million
Q3 2022 Mar 30, 2023	BUY	$5.45 - $8.13 $9,128 - $13,617	1,675 Added 71.06%	4,032 $27,000
Q3 2022 Nov 14, 2022	BUY	$5.45 - $8.13 $9,128 - $13,617	1,675 Added 71.06%	4,032 $27,000
Q2 2022 Jun 20, 2023	BUY	$4.77 - $6.67 $11,242 - $15,721	2,357 New	2,357 $14,000
Q2 2022 Mar 30, 2023	SELL	$4.77 - $6.67 $8,380 - $11,719	-1,757 Reduced 42.71%	2,357 $14,000
Q2 2022 Aug 11, 2022	SELL	$4.77 - $6.67 $8,380 - $11,719	-1,757 Reduced 42.71%	2,357 $15,000
Q1 2022 Jun 20, 2023	BUY	$3.34 - $5.56 $13,740 - $22,873	4,114 New	4,114 $19,000
Q1 2022 Mar 30, 2023	SELL	$3.34 - $5.56 $12,234 - $20,366	-3,663 Reduced 47.1%	4,114 $19,000
Q1 2022 May 12, 2022	BUY	$3.34 - $5.56 $13,740 - $22,873	4,114 New	4,114 $19,000
Q4 2021 Feb 15, 2022	SELL	$4.81 - $11.92 $37,407 - $92,701	-7,777 Closed	0 $0
Q3 2021 Jun 21, 2023	BUY	$11.34 - $21.37 $88,191 - $166,194	7,777 New	7,777 $93,000
Q2 2021 Jun 21, 2023	BUY	$19.4 - $28.71 $150,873 - $223,277	7,777 New	7,777 $164,000
Q2 2021 Aug 16, 2021	BUY	$19.4 - $28.71 $150,718 - $223,047	7,769 Added 97112.5%	7,777 $164,000
Q1 2021 Jun 26, 2023	BUY	$25.12 - $36.89 $195,358 - $286,893	7,777 New	7,777 $218 Million
Q1 2021 May 14, 2021	SELL	$25.12 - $36.89 $195,157 - $286,598	-7,769 Reduced 99.9%	8 $218,000
Q4 2020 Jun 22, 2023	BUY	$24.2 - $35.76 $188,203 - $278,105	7,777 New	7,777 $202,000
Q3 2020 Jun 26, 2023	BUY	$31.18 - $52.71 $242,486 - $409,925	7,777 New	7,777 $289,000
Q2 2020 Jun 26, 2023	BUY	$30.04 - $51.31 $233,621 - $399,037	7,777 New	7,777 $399,000
Q1 2020 Jul 12, 2023	BUY	$27.44 - $73.84 $213,400 - $574,253	7,777 New	7,777 $245,000
Q4 2019 Jul 12, 2023	BUY	$35.4 - $59.82 $275,305 - $465,220	7,777 New	7,777 $463,000
Q4 2019 Mar 30, 2023	SELL	$35.4 - $59.82 $51,400 - $86,858	-1,452 Reduced 15.73%	7,777 $463,000
Q4 2019 Feb 14, 2020	SELL	$35.4 - $59.82 $51,400 - $86,858	-1,452 Reduced 15.73%	7,777 $464,000
Q3 2019 Jul 12, 2023	BUY	$34.47 - $47.53 $318,123 - $438,654	9,229 New	9,229 $338,000
Q3 2019 Mar 30, 2023	BUY	$34.47 - $47.53 $52,773 - $72,768	1,531 Added 19.89%	9,229 $338,000
Q3 2019 Nov 14, 2019	BUY	$34.47 - $47.53 $52,773 - $72,768	1,531 Added 19.89%	9,229 $338,000
Q2 2019 Jul 12, 2023	BUY	$40.1 - $52.33 $308,689 - $402,836	7,698 New	7,698 $358,000
Q1 2019 Jul 13, 2023	BUY	$40.11 - $53.57 $308,766 - $412,381	7,698 New	7,698 $309,000
Q1 2019 Mar 30, 2023	BUY	$40.11 - $53.57 $147,043 - $196,387	3,666 Added 90.92%	7,698 $309,000
Q1 2019 May 16, 2019	SELL	$40.11 - $53.57 $125,183 - $167,191	-3,121 Reduced 28.85%	7,698 $309,000
Q1 2019 May 15, 2019	BUY	$40.11 - $53.57 $125,183 - $167,191	3,121 Added 40.54%	10,819 $499,000
Q4 2018 Jul 13, 2023	BUY	$36.99 - $59.11 $284,749 - $455,028	7,698 New	7,698 $354,000
Q4 2018 Feb 14, 2019	BUY	$36.99 - $59.11 $222,383 - $355,369	6,012 Added 356.58%	7,698 $354,000
Q3 2018 Jul 13, 2023	BUY	$40.74 - $51.41 $313,616 - $395,754	7,698 New	7,698 $342 Million
Q3 2018 Nov 14, 2018	SELL	$40.74 - $51.41 $244,928 - $309,076	-6,012 Reduced 78.1%	1,686 $75,000
Q2 2018 Aug 15, 2018	BUY	$36.2 - $76.4 $80,508 - $169,913	2,224 Added 40.63%	7,698 $0
Q4 2017 Feb 15, 2018	SELL	$43.47 - $67.43 $235,694 - $365,605	-5,422 Reduced 49.76%	5,474 $360,000
Q2 2017 Aug 14, 2017	BUY	N/A	10,896	10,896 $504,000

Others Institutions Holding ESPR

# of Institutions

206

Shares Held

128M

Call Options Held

1.67M

Put Options Held

930K

View Full List

About Esperion Therapeutics, Inc.

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $156M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

More about ESPR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.

Account